EA201991818A1 - Лечение рака - Google Patents
Лечение ракаInfo
- Publication number
- EA201991818A1 EA201991818A1 EA201991818A EA201991818A EA201991818A1 EA 201991818 A1 EA201991818 A1 EA 201991818A1 EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A1 EA201991818 A1 EA 201991818A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer treatment
- erdafitinib
- provides
- present
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (fr) | 2017-02-06 | 2018-02-02 | Traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991818A1 true EA201991818A1 (ru) | 2020-02-05 |
Family
ID=60702421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991818A EA201991818A1 (ru) | 2017-12-20 | 2018-02-02 | Лечение рака |
Country Status (5)
| Country | Link |
|---|---|
| EA (1) | EA201991818A1 (fr) |
| MA (1) | MA47408B1 (fr) |
| PT (1) | PT3576740T (fr) |
| TW (1) | TWI798199B (fr) |
| WO (1) | WO2018141921A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210052A1 (ar) * | 2018-09-21 | 2021-03-18 | Janssen Pharmaceutica Nv | علاج سرطان الأوعية الصفراوية |
| WO2020131674A1 (fr) * | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer |
| JP2022521173A (ja) * | 2019-02-12 | 2022-04-06 | ヤンセン ファーマシューティカ エヌ．ベー． | 癌治療 |
| US20220202703A1 (en) * | 2019-03-15 | 2022-06-30 | Poly-Med, Inc. | In situ gel-forming delivery systems, methods and compositions |
| BR112021019203A2 (pt) * | 2019-03-29 | 2021-11-30 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial |
| JP2022534118A (ja) * | 2019-05-31 | 2022-07-27 | キューイーディー セラピューティクス，インコーポレイテッド | 泌尿器系がんを治療する方法 |
| WO2021119108A1 (fr) * | 2019-12-09 | 2021-06-17 | Cedars-Sinai Medical Center | Utilisation d'inhibiteurs de fgfr pour le traitement de sujets présentant un retard de croissance idiopathique |
| IL295514A (en) * | 2020-02-12 | 2022-10-01 | Janssen Pharmaceutica Nv | fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle-invasive bladder cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (ar) * | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
-
2018
- 2018-02-02 TW TW107103846A patent/TWI798199B/zh active
- 2018-02-02 EA EA201991818A patent/EA201991818A1/ru unknown
- 2018-02-02 MA MA47408A patent/MA47408B1/fr unknown
- 2018-02-02 PT PT187022991T patent/PT3576740T/pt unknown
- 2018-02-02 WO PCT/EP2018/052694 patent/WO2018141921A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| TWI798199B (zh) | 2023-04-11 |
| MA47408B1 (fr) | 2023-08-31 |
| MA47408A (fr) | 2019-12-11 |
| WO2018141921A1 (fr) | 2018-08-09 |
| PT3576740T (pt) | 2023-08-18 |
| TW201839399A (zh) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| EA201991818A1 (ru) | Лечение рака | |
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| PH12017501999A1 (en) | K-ras modulators | |
| MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
| MX2016001963A (es) | Metodo de seleccion. | |
| BR112017000130A2 (pt) | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
| EA202091881A1 (ru) | Соединения для лечения боли | |
| EA202191086A1 (ru) | Комбинированная терапия меланомы | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| BR112018012116A2 (pt) | terapia intravesical para câncer de bexiga | |
| EP3674398A4 (fr) | Échovirus pour le traitement de tumeur | |
| CY1125266T1 (el) | To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων | |
| EA202192163A1 (ru) | Лечение рака | |
| EA202190833A1 (ru) | Bt1718 для применения при лечении рака |